More Ways to Connect
  Facebook Twitter YouTube RSS
  LinkedIn PInterest Instagram
Search
News
Michael Borchers, PhD, is an assistant professor of environmental health at UC.
PHOTOS: 
1

Michael Borchers, PhD, is an assistant professor of environmental health at UC.
|
2

According to the Centers for Disease Control and Prevention, smoking is the single most common cause of preventable death and disease in the United States.
Back Next
Publish Date: 02/09/09
Media Contact: AHC Public Relations, (513) 558-4553
print
PDF download
RSS feed
related news
share this
Body's Defenses May Worsen Chronic Lung Diseases in Smokers

Cincinnati—Although the immune system is designed to protect the body from harm, it may actually worsen one of the most difficult-to-treat respiratory diseases: chronic obstructive pulmonary disorder (COPD), according to new University of Cincinnati (UC) research.

 

In a preclinical research study, UC environmental health scientists have identified a link between cigarette smoke and activation of a specific cellular receptor (NKG2D) critical to immune system activation. They say the finding is key to understanding COPD disease progression and developing future interventional drug therapies.  

 

“People have historically believed that if you smoke, you suppress the immune system. We’ve shown that you actually activate certain parts of the immune system and it could potentially work against you,” explains Michael Borchers, PhD, lead investigator of the study and UC assistant professor of environmental health.

 

Borchers and his team report their findings in the March 2009 issue of theJournal of Clinical Investigation. The study appears online ahead of print Feb. 9, 2009. It is the first study to report data defining a link between the immune system and COPD disease progression and severity.

 

COPD is a progressive pulmonary disease believed to be caused by long-term cigarette smoking. The irreversible and incurable condition is characterized by emphysema and severe inflammation of the lung tissue.

 

Previous research had suggested that immune cells (lymphocytes) contributed to chronic inflammation, a key indicator of COPD; however, it was unclear whether this caused extensive cellular damage.

 

For this study, Borchers’ team developed a transgenic mouse model to further examine how the immune system responds to chronic inflammation indicative of COPD. His team hypothesized that when tissue was damaged, the cells would send signals to the immune system indicating they are transformed—similar to cancer or virally infected cells—and must be destroyed.

 

Scientists examined molecular signaling pathways in lung tissue exposed to cigarette smoke and found a strong correlation between cellular stress signals, activation of the immune system and development of COPD-like disease.

 

This method was repeated and cross-referenced in tissue samples from a human cohort that included non-smokers, smokers with COPD and smokers who did not develop COPD. In patients who had never smoked, there was a complete absence of the NKG2D signal. Current and former smokers who developed the disease expressed signals that correlated with severe COPD disease.

 

By combining both sets of data, they determined that cigarette smoke set off a molecular chain of events resulting in activation of a specific receptor—NKG2D—in lung cells, causing the immune system to attack stressed (damaged) lung tissue.

 

“Our study is evidence that when the lungs are exposed to chronic damage from cigarette smoke, at some point that damage exceeds the body’s natural ability to repair tissue and can start to contribute to COPD instead of protecting against it,” Borchers says.

 

Borchers intends to expand this research using other genetically altered mouse models to explore the relationship between the NKG2D receptor and other immune pathways involved in of alterations in the immune system of COPD patients.

 

Funding for the multi-institutional study comes from the National Institute of Environmental Health Sciences. UC thoracic surgeons Michael Reed, MD, and Sandra Starnes, MD, and investigators at the Institut Municipal d’Investigació Mèdica in Barcelona, Spain, provided tissue samples for the study.



 back to list | back to top